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M
alaria has been eliminated 
from a large part of the world. 
By the mid-twentieth century 
both North America and Europe were 
free of the disease, although both 
had suffered greatly during the prior 
century [1,2]. While a variety of means 
were used to achieve this eradication, 
the most important are thought to 
be reducing the number of breeding 
sites for malaria vectors and improving 
residential areas to separate humans 
from mosquitoes. 
Other parts of the world have not 
been so fortunate. In sub-Saharan 
Africa, it is now estimated that there 
are more than 360 million clinical cases 
and one million deaths due to malaria 
each year [3,4]. Furthermore, despite 
ambitious goals such as those of the 
Roll Back Malaria Initiative to halve 
malaria deaths by 2010, mortality from 
the disease has actually risen halfway 
through the program [5]. Clearly the 
tools we have to control malaria, or the 
ways in which we are using them, are 
not working.
The failure of existing methods for 
malaria control has sparked interest in 
several new approaches. These include 
better and cheaper antimalarial drugs 
[6], renewed efforts to find a vaccine 
[7], and the development of genetically 
modified mosquitoes (GMMs) designed 
either to reduce population sizes or 
to replace existing populations with 
vectors unable to transmit the disease. 
In this review we describe some of the 
efforts currently underway to create 
GMMs and assess some of the obstacles 
they face.
Background
Malaria in humans results from 
infection by any of five species of 
Plasmodium: P. falciparum, P. vivax,
P. ovale, P. malariae, and P. knowlesi.
These are transmitted to humans 
by approximately 50 species of 
mosquitoes, all belonging to the genus 
Anopheles. In sub-Saharan Africa, the 
vast majority of deaths are caused by P.
falciparum transmitted by An. gambiae
and the closely related An. arabiensis.
These species are difficult to work 
with in the laboratory, so other model 
systems of malaria are often used in 
laboratory studies.
Most species of mosquitoes do not 
transmit malaria, and even among 
species that do, many individuals seem 
incapable of transmitting the disease, 
i.e., are refractory. Accordingly, there 
is reason to hope that the genes 
that permit malarial infections in 
mosquitoes can be identified and then 
replaced or altered in terms of their 
function. In this way, it is hoped that 
mosquito populations will become 
refractory to the parasite, eventually 
leading to malaria transmission being 
halted.
A variety of methods for engineering 
refractory mosquitoes are currently 
being studied and show promise 
for malaria control. The laboratory 
of Marcelo Jacobs-Lorena at Johns 
Hopkins University has successfully 
engineered mosquitoes that confer 
resistance to rodent malaria [8]. Their 
approach was to first identify receptor 
sites for proteins that the parasite 
requires to pass through the gut after 
ingestion. They next produced small 
proteins that saturate the receptor sites 
and hence block amplification and 
transmission of the parasite (Figure 
1). Future research in this area should 
focus on optimizing refractory genes to 
effectively confer resistance to human 
malaria.
Other methods for generating 
refractoriness involve using antibodies 
that kill parasites within the mosquito 
[9] and discovering genes that 
govern refractoriness in natural 
populations [10]. A great deal is being 
discovered about the immune system 
of mosquitoes [11], leading many 
researchers in this field to believe that 
an effective gene construct to reduce 
the ability of mosquitoes to transmit 
malaria is not far away.
Drive Systems
More problematic is the means of 
driving a refractory construct quickly 
and efficiently through the vector 
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FIVE KEY PAPERS IN THE FIELD
Marshall, 2008 [18] This article focuses 
on TEs as a drive system and models the 
impact of dissociation between the drive 
system and refractory gene. It references 
much of the important work to this time 
on TEs.
Chen et al., 2007 [20] This article 
describes the biology and potential uses 
of a synthetic Medea element observed 
to spread through laboratory Drosophila
populations.
James, 2005 [19] A general overview 
of the criteria required by gene drive 
systems intended to drive refractory 
genes into mosquito populations.
Alphey et al., 2002 [27] A discussion of 
the benefits, risks, and research priorities 
associated with using transgenic insects 
to control vector-borne diseases.
Ito et al., 2002 [8] An historic paper 
that describes one of the first candidate 
antiparasitic genes that works in a 
disease vector model system in the 
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mosquito population so that the 
population of susceptible mosquitoes 
will be replaced. Transposable 
elements (TEs) were one of the first 
gene drive systems to gain widespread 
attention for population replacement 
[12]. These elements are able to spread 
quickly through a population due to 
their ability to replicate within a host 
genome and hence to be inherited 
more frequently in the offspring’s 
genome. This increase in inheritance 
enables TEs to spread even in the 
presence of a fitness cost to the host 
[13]. It has also led to their widespread 
prevalence among many taxa, to the 
extent that various families of TEs 
represent 47% of the Aedes aegypti
mosquito genome [14].
One source of encouragement 
for the use of TEs in population 
replacement is the observation that 
the P element spread through most 
of the global Drosophila melanogaster
population within the span of a few 
decades following a natural acquisition 
from D.  willistoni [15]. It is hoped that 
such an invasion could be repeated 
in a mosquito species using a TE 
that is attached to a refractory gene 
conferring resistance to malaria. 
Ideally, such an invasion would be 
repeated in each of the major mosquito 
species that transmits malaria.
Despite initial excitement, TEs 
have become less favored as a means 
of population replacement in recent 
years. The first major hurdle has been 
the failure to introduce a highly active 
TE into An. gambiae—the main vector 
of malaria in sub-Saharan Africa. TEs 
tend to repress their activity over time 
to avoid corrupting the host genome. 
Many TEs, including the P element, 
accumulate mutations leading to 
their inactivation. This may make the 
discovery of a highly active TE more 
challenging than originally anticipated. 
Additionally, preliminary data 
suggest other reasons that TEs may 
be ill-suited to driving foreign DNA 
into populations. A study on the 
Himar1 mariner element suggests that 
TE activity declines substantially with 
increasing size [16]. Given current 
refractory gene sizes (e.g., [17]), the 
mariner element is estimated to have 
its replication rate reduced by at least 
95% when burdened by a refractory 
construct [16]. Its drive would have to 
be very strong in order to suffer such a 
decline in replication.
This is compounded by the fact 
that TEs are particularly vulnerable 
to losing internal sequences during 
replication. Mathematical modeling 
suggests that, if the refractory gene 
is lost from the TE at a modest rate, 
the malaria-susceptible TE will return 
to again dominate the population 
[18]. Therefore, even if active TEs 
can be identified, their ability to drive 
refractory genes into a population is 
questionable.
Disenchantment with TEs as a 
means of population replacement has 
coincided with interest in several other 
gene drive systems. Some of the most 
promising drive mechanisms currently 
being investigated include Medea
elements, homing endonuclease genes 
(HEGs), engineered underdominance 
constructs, and the intracellular 
bacterium Wolbachia. Other systems 
that are being investigated include 
engineered underdominance 
constructs and meiotic drive [19]. 
The favorability of one gene drive 
system over another will depend on its 
ability to quickly and efficiently spread 
a refractory gene. However, this on 
its own is not enough. The ideal gene 
drive system will also address ecological, 
epidemiological, and social concerns 
that such a system engenders and 
minimize the likelihood of any risks. In 
our opinion, the most promising system 
at present is Medea.
Medea has attracted much attention 
as a tool for population replacement 
in recent years, following the 
observation that an engineered Medea
doi:10.1371/journal.pmed.1000020.g001
Figure 1. Mechanism for Blocking Malaria Transmission in the Mosquito
Left: Mosquitoes become infected with the malaria parasite upon taking an infected human blood-meal. This produces an oocyst in the mosquito’s gut 
wall (light red). When the oocyst ruptures, it releases sporozoites that pass through the gut (dark red) and into the hemocoel (white). The sporozoites 
are then amplified and migrate through the mosquito’s body to the salivary glands, ready to infect a new human. Right: The laboratory of Marcelo 
Jacobs-Lorena at Johns Hopkins University has identified receptor sites for proteins that are necessary for the malaria parasite to pass through the gut 
wall after the oocyst ruptures. The same receptors are involved with the passage of sporozoites into the salivary glands. The laboratory has produced 
small proteins that preferentially occupy these sites (blue), blocking transmission of sporozoites through the gut wall and into the salivary glands. The 
appropriate gene constructs have been introduced into An. stephensi mosquitoes, thus rendering them refractory to P. berghei (a model system for 
human malaria).PLoS Medicine  |  www.plosmedicine.org 0166 February 2009  |  Volume 6  |  Issue 2  |  e1000020
element is able to rapidly spread 
through D. melanogaster populations 
in the laboratory [20]. The design 
of this synthetic element is based on 
a naturally occurring selfish genetic 
element first discovered in a species of 
flour beetle, Tribolium castaneum. Medea
is able to rapidly spread through a 
population in the presence of a fitness 
cost by distorting the offspring ratio 
in its favor. It does this by causing the 
death of all offspring of heterozygous 
females that do not inherit the allele, 
thus giving rise to its name—an 
acronym for maternal-effect dominant 
embryonic arrest, with reference to 
the mythological Greek figure who 
murdered her own children.
The synthetic Medea element 
developed by Chen et al. [20] works 
by the hypothesis that Medea encodes 
both a maternally expressed toxin and 
a zygotically expressed antidote. The 
toxin causes the death of all progeny 
lacking the Medea allele, and the 
antidote rescues Medea-bearing progeny 
from an otherwise imminent death 
(Figure 2). In this way, the proportion 
of Medea-bearing individuals is 
increased with each generation; and 
it is hoped that an attached refractory 
gene conferring resistance to malaria 
could come along for the ride.
Medea does not suffer from many of 
the ailments inflicted upon TEs—an 
active Medea element has been 
engineered, its spread is not retarded 
by the insertion of foreign DNA, 
and a solution has been proposed to 
minimize the rate of dissociation of 
refractory genes [20]. Additionally, in 
the event that a refractory gene should 
be recalled following an environmental 
release with unwanted consequences, 
it has been proposed that another 
strain of Medea could be introduced 
to replace the first, thus removing the 
refractory gene from the population.
One attractive feature of Medea
is that its rate of spread is strongly 
dependent on its release ratio [21]. 
While Medea will spread very quickly 
following a large intentional release, 
it is very likely to go extinct following 
a small accidental release [22]. This 
is particularly important since it is 
impossible to guarantee that there 
will be no escapes while outdoor cage 
trials assess the potential outcomes of 
an environmental release [23]. Medea
therefore presents a desirable balance 
between invasiveness and containment. 
At present, there is an active effort to 
construct Medea systems for mosquitoes, 
but as yet no such systems have been 
made.
HEGs are another system for 
which there are active development 
efforts. These genes are able to spread 
through a population by expressing an 
endonuclease that creates a double-
stranded break at a highly specific 
site lacking the HEG. Homologous 
DNA repair then copies the HEG to 
the cut chromosome, thus increasing 
its representation over subsequent 
generations [24]. 
Next Steps in Research
The first requirement of any transgenic 
mosquito project will be the discovery 
of genes that confer resistance to 
human vector-borne diseases. The 
proof of principle has been shown for 
rodent and chicken malaria, and it 
remains to optimize genes to confer 
resistance to human malaria. Several 
refractory genes will be necessary for a 
successful intervention both to improve 
the efficacy of refractoriness, and to 
reduce the probability that resistance to 
antipathogen genes will emerge in the 
Plasmodium population.
Possibly more challenging will be 
the optimization of gene drive systems 
to deliver these refractory genes into 
mosquito populations. Medea has been 
shown to drive population replacement 
in Drosophila; and future research 
should work towards repeating this in 
mosquitoes. If this can be achieved, 
Medea will be a very promising 
candidate for population replacement; 
however, potential hazards for Medea
and other gene drive systems must 
be identified and responded to, such 
as their ability to spread through 
reproductively isolated populations, 
and their persistence following an 
accidental release. Mathematical 
modeling can assist in assessing the 
severity of these concerns.
A broad study is required of the 
ecology of mosquito vectors through 
which the refractory genes are 
intended to be driven. Comprehensive 
ecological studies have been carried 
out in selected regions (e.g., [25]); 
doi:10.1371/journal.pmed.1000020.g002
Figure 2. Parental Crosses Representing the Reproductive Advantage of the Medea Allele
Females carrying the Medea allele produce a maternally expressed toxin (red outer circle) that is 
deleterious to their offspring. Offspring who carry the Medea allele are rescued by a zygotically 
expressed antidote (green inner circle) expressed by the same allele. Offspring of heterozygous 
females who do not inherit the Medea allele are killed by the toxin because they lack the 
antidote (yellow represents lack of the toxin/antidote). This distorts the offspring ratio in favor of 
the Medea allele.PLoS Medicine  |  www.plosmedicine.org 0167 February 2009  |  Volume 6  |  Issue 2  |  e1000020
however, these must be extended 
to other regions of Africa to gain a 
broader picture of species distributions 
and rates of gene flow. Malaria is a 
complex disease, and the biology of its 
vectors is also complex. In most parts of 
Africa, there is more than one species 
of Anopheles that transmits malaria. If 
hybridization among species is judged 
to be insufficient, then the feasibility 
of altering several species of malaria 
vectors will need to be considered. 
We have focused our review on the 
effort to produce GMMs for malaria 
control; however, developing GMMs 
for dengue control will likely be 
achieved much earlier. Dengue virus, 
transmitted by the vector Ae. aegypti,
is likely the second-most important 
vector-borne disease system after 
malaria. It is also much simpler than 
malaria—Ae. aegypti is easier to rear and 
experiment with than An. gambiae, and 
dengue does not have a complicated 
life cycle like Plasmodium. Much of 
the current work on GMMs is being 
conducted with dengue virus, and 
many of the problems confronting 
vector replacement will probably be 
worked out first with this system.
Finally, a large number of ethical 
concerns must be addressed and 
resolved satisfactorily before GMMs 
can be introduced. These include 
questions about the meaning of 
informed consent in communities that 
are largely illiterate, unfamiliar with 
genetic modification, and sometimes 
uneducated on the role of mosquitoes 
in disease transmission. These consent 
issues are confounded by the possibility 
of unknown and potentially serious 
side effects of a release, for example, 
an increase in the transmission of 
non-target diseases. Furthermore, 
acceptance by one community, or 
even country, is likely to affect many 
of its neighbors, whether they agree 
with the decision to release or not. 
Such a release may occur accidentally 
from an outdoor cage trial; however, 
an intentional release cannot be 
conducted prior to evaluation in cage 
trials.
Despite this, mosquito-borne diseases 
kill in excess of a million people 
every year, mostly children under five 
years old. GMMs offer some hope of 
reducing this burden of disease, and 
hence their risks, both known and 
unknown, must be weighed against the 
certain toll of inaction. In addition to 
some helpful initial studies [22,26,27], 
there is a clear need for much more 
analysis of the human research 
participant issues posed by these new 
methods.
Conclusion
Malaria control with transgenic 
mosquitoes will be challenging; 
however, recent advances suggest that 
it may be a possibility in the foreseeable 
future. Progress towards discovering 
refractory genes for rodent malaria 
and gene drive systems for Drosophila
provide hope that similar advances 
may be made for human malaria in 
mosquito vector species.
That said, the African malaria 
burden has proved exceptionally 
difficult to diminish by all means 
tried thus far; and it is unlikely that 
transgenic mosquitoes will provide 
an all-in-one solution. Transgenic 
mosquitoes should be considered 
within the context of an integrated 
vector management strategy which 
should also include insecticide-treated 
bed-nets, indoor residual spraying with 
insecticides, and treatment of infected 
individuals with antimalarial drugs. 
Integrated strategies will be a necessity 
for any successful African malaria 
control program [28]; and transgenic 
mosquitoes should be considered as a 
potential ingredient in the future goal 
of continent-wide disease control.  
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